Clinical Trials

BLOCK ROP: This trial will examine the safety of using Bevacizumab (Avastin) to treat children with aggressive ROP that is failing despite laster treatment. This drug targets the growth factor (Vascular Endothelial Growth Factor - VEGF) that is responsible for causing the abnormal blood vessel growth in children with ROP.

Inter-Institutional Comparison of ROP Incidence: This study will examine factors that contribute to the rate of ROP and determine whether specific neonatal practice patterns can reduce the frequency of ROP in very low birthweight premature children.

ROP in the Micropreemie: This study will characterize the rate of ROP in children born at 23 - 24 weeks gestation. Very little is known about this patient population or their risk of ROP. The study will also address whether these children have a poorer response rate to traditional laser therapy.

ROP SPEED: This study will compare the ability of an ROP screener to evaluate ROP based on a physical in-person exam versus examining a digital fundus photograph. This will help identify the most effective and efficient method for ROP screening.